Loading organizations...
Loading organizations...
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Sep 1, 2016 | AnTolRx | $4.0M Series A | Pfizer | RiverVest, JDRF |
| Feb 1, 2015 | Lysosomal Therapeutics | $20.0M Series A | Atlas Venture | Advent Life Sciences, Apollo Health Ventures, ARCH Venture Partners, Hatteras Venture Partners, Omega Funds, Polaris Partners, Red Tree Venture Capital, Roche Venture Fund, Vivo Capital, Bob Carpenter, Henri Termeer, Lilly Ventures, Partners Innovation Fund, Roche, Sanofi Ventures |
| May 1, 2014 | Lysosomal Therapeutics | $5.0M Seed | Atlas Venture | Advent Life Sciences, Apollo Health Ventures, ARCH Venture Partners, Hatteras Venture Partners, Omega Funds, Polaris Partners, RA Capital, Red Tree Venture Capital, Roche Venture Fund, Vivo Capital, Steve Hall, Reza Halse, Carole Nuechterlein, Bernard Davitian |